Investopedia: Novo Nordisk Getting Its Trial By Fire

The past year or so has shown that Novo Nordisk (NYSE: NVO ) isn't immune from seeing some serious challenges to its business. Betwee...

Investopedia: Can Sanofi Investors Just Blame It On Rio?

Sanofi (NYSE: SNY ) was supposed to be a relatively solid Big Pharma company in 2013. True, the company is going through some pressures f...

Seeking Alpha: Forget Arena Vs. Vivus - Zafgen May Be The Ultimate Winner

As an investor and writer with no financial stake in any of the companies involved, watching the message board battles between Arena ( ARNA...

MassDevice: The Strange Case Of The Diabetes Market

It wasn't so long ago when diabetes was one of the hot sectors of med-tech where many companies felt they had to have a presence, no m...

Investopedia: Amgen Chased By The Bubble

There are two relatively heated debates that bear directly on Amgen (Nasdaq: AMGN ) and its stock. First, is Amgen still really a biotech,...